

Abstract of the Disclosure

The invention relates to copper agonists that bind on the copper binding site of APP and/or exert an inhibiting effect on the release of the amyloid A β peptide participating in the emergence of Alzheimer's disease. The invention also relates to the drugs containing said copper agonists or to the utilization of said copper agonists for the preparation of a drug for the prevention and/or treatment of Alzheimer's disease. The invention further relates to a method for identifying copper agonists having the desired effect described in the invention.